NCT05256641 2026-03-10
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Jonsson Comprehensive Cancer Center
Phase 1/2 Recruiting
Clinical Trials
6 trialsNCT02029443 2026-02-06
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Acerta Pharma BV
Phase 1/2 Active not recruiting
NCT06564038 2026-02-05
Soundtrack-E
AstraZeneca
Phase 1/2 Recruiting
NCT03932331 2026-01-29
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
AstraZeneca
Phase 1/2 Active not recruiting
NCT04855695 2026-01-21
Avo In R/R And Previously Untreated MCL
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT02586857 2026-01-12
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Acerta Pharma BV
Phase 1/2 Active not recruiting